Get started
Author

Ken Masubuchi

Observed names: K. Masubuchi, KEN MASUBUCHI
ORCID: 0000-0001-7440-441X
Observed ORCID: 0000-0001-7440-441X
OpenAlex ID: A5087738157
C-Jun-NH2-Terminal Kinase Mediates Expression of Connective Tissue Growth Factor Induced by Transforming Growth Factor-β1 in Human Lung Fibroblasts
2003 · Mitsuyoshi Utsugi, Kunio Dobashi, et al. · American Journal of Respiratory Cell and Molecular Biology · 89
Glutathione redox regulates TGF‐β‐induced fibrogenic effects through Smad3 activation
2008 · Akihiro Ono, Mitsuyoshi Utsugi, et al. · FEBS Letters · 25
PDF
A Prospective Phase II Trial of First-Line Osimertinib for Patients With EGFR Mutation-Positive NSCLC and Poor Performance Status (OPEN/TORG2040)
2025 · Tomoya Fukui, Nobuaki Mamesaya, et al. · Journal of Thoracic Oncology · 22
Using the neutrophil‐to‐lymphocyte ratio to predict the outcome of individuals with nonsquamous non‐small cell lung cancer receiving pembrolizumab plus platinum and pemetrexed
2023 · Hisao Imai, Satoshi Wasamoto, et al. · Thoracic Cancer · 12
PDF
Post‐progression survival after atezolizumab plus carboplatin and etoposide as first‐line chemotherapy in small cell lung cancer has a significant impact on overall survival
2022 · Ken Masubuchi, Hisao Imai, et al. · Thoracic Cancer · 12
Prognostic Potential of the Prognostic Nutritional Index in Non-Small Cell Lung Cancer Patients Receiving Pembrolizumab Combination Therapy with Carboplatin and Paclitaxel/Nab-Paclitaxel
2023 · Fuyumi Nishihara-Kato, Hisao Imai, et al. · Oncology · 11
Exploration of clinical Biomarkers for guiding treatment selection between chemotherapy and combination therapy with Atezolizumab, Bevacizumab, Carboplatin, and Paclitaxel in EGFR-Mutant NSCLC patients after EGFR-TKI Therapy: The SPIRAL-STEP study
2025 · Kenji Morimoto, Tadaaki Yamada, et al. · Lung Cancer · 10
PDF
Course of postoperative relapse in non‐small cell lung cancer is strongly associated with post‐progression survival
2021 · Hisao Imai, Ryoichi Onozato, et al. · Thoracic Cancer · 9
PDF
Efficacy and Safety of First-line Pembrolizumab Plus Platinum and Pemetrexed in Elderly Patients with Non-squamous Non-small-cell Lung Cancer
2024 · Satoshi Wasamoto, Hisao Imai, et al. · Internal Medicine · 7
Ambroxol inhibits platelet-derived growth factor production in human monocytic cells
2002 · Mitsuyoshi Utsugi, Kunio Dobashi, et al. · European Journal of Pharmacology · 7
Durvalumab, carboplatin, and etoposide in patients who are treatment-naive with extensive-stage small-cell lung cancer and poor performance status (NEJ045A): a single-arm phase 2 trial
2025 · Tetsuhiko Asao, Yu Saida, et al. · The Lancet Respiratory Medicine · 5
PDF
Durvalumab after concurrent chemoradiotherapy for sensitizing epidermal growth factor receptor-mutant stage III non-small cell lung cancer: A Japanese Real-World data analysis
2025 · Toshiya Fujisaki, Eisaku Miyauchi, et al. · Lung Cancer · 5
PDF
A retrospective evaluation of therapeutic efficacy and safety of chemoradiotherapy in older patients (aged ≥ 75 years) with limited-disease small cell lung cancer: insights from two institutions and review of the literature
2024 · Ayako Shiono, Hisao Imai, et al. · Radiology and Oncology · 4
PDF
Satisfaction in older patients by geriatric assessment using a novel tablet-based questionnaire system: A cluster-randomized, phase III trial of patients with non–small-cell lung cancer (ENSURE-GA study; NEJ041/CS-Lung001).
2023 · Sayo Soda, Kie Mirokuji, et al. · Journal of Clinical Oncology · 4
The Glasgow Prognostic Score as a Predictor of Survival after Chemoradiotherapy for Limited-Disease Small Cell Lung Cancer
2024 · Satoshi Endo, Hisao Imai, et al. · Oncology · 3
Management of Lung Cancer-Associated Malignant Pericardial Effusion with Intrapericardial Administration of Carboplatin: A Retrospective Study
2021 · Hisao Imai, Kyoichi Kaira, et al. · Current Oncology · 3
PDF
Impact of EGFR Mutation Subtypes on Response to Chemoimmunotherapy and Chemotherapy in Non-Small-Cell Lung Cancer After EGFR-TKI Failure
2025 · Kenji Morimoto, Tadaaki Yamada, et al. · Targeted Oncology · 2
Mirtazapine plus granisetron and dexamethasone for carboplatin-induced nausea and vomiting in patients with thoracic cancers: A prospective multicenter phase II trial
2024 · Hirotoshi Iihara, Masamichi Iwai, et al. · Lung Cancer · 2
Post-Progression Survival Highly Influences Overall Survival in Driver Gene Mutation/Translocation Negative or Unknown Type of Non-Small Cell Lung Cancer
2021 · Hisao Imai, Ryoichi Onozato, et al. · Oncology · 2
Candida Glabrata Fungemia After Amputation of an Infected Diabetic Foot
2010 · Takeshi Fujiwara, Takashi Nagai, et al. · The Kitakanto Medical Journal · 2
PDF
An Overwhelming Postsplenectomy Infection Syndrome Associated with Diabetes Mellitus
2009 · Mai Tomizawa, Takashi Nagai, et al. · The Kitakanto Medical Journal · 2
PDF
Real-world treatment outcomes before and after chemoimmunotherapy approval in EGFR-mutant NSCLC after EGFR-TKI failure: a Japanese cohort study
2025 · Kenji Morimoto, Tadaaki Yamada, et al. · International Journal of Clinical Oncology · 1
Clinical significance of post‑progression survival after chemoradiotherapy on overall survival in limited‑disease small cell lung cancer
2025 · Ayako Shiono, Hisao Imai, et al. · Molecular and Clinical Oncology · 1
PDF
A multicenter, prospective phase II trial of first-line osimertinib treatment for patients with poor performance status and EGFR mutation–positive non-small cell lung cancer (OPEN/TORG2040).
2024 · Nobuaki Mamesaya, Tomoya Fukui, et al. · Journal of Clinical Oncology · 1
Clinical impact of post-progression survival in patients with locally advanced non-small cell lung cancer after chemoradiotherapy
2022 · Hisao Imai, Daijiro Kobayashi, et al. · Radiology and Oncology · 1
PDF
Works count: 35
Citation count: 242
H-index: 8
I10-index: 7
Year
Topic
Type